MayTech Global Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

MayTech Global Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-350	Closed	-$36.2K	–	33
2022 Q4	$36.2K	Buy	+350	New	+$32.9K	0.01%	50
2022 Q3	–	Sell	-350	Closed	-$29K	–	35
2022 Q2	$29K	Hold	350	–	–	0.01%	61
2022 Q1	$27K	Hold	350	–	–	0.01%	67
2021 Q4	$31K	Hold	350	–	–	0.01%	70
2021 Q3	$27K	Hold	350	–	–	0.01%	58
2021 Q2	$29K	Hold	350	–	–	0.01%	57
2021 Q1	$26K	Hold	350	–	–	0.01%	49
2020 Q4	$31K	Hold	350	–	–	0.01%	46
2020 Q3	$27K	Hold	350	–	–	0.01%	43
2020 Q2	$43K	Hold	350	–	–	0.01%	42
2020 Q1	$30K	Hold	350	–	–	0.01%	42
2019 Q4	$30K	Hold	350	–	–	0.01%	41
2019 Q3	$24K	Hold	350	–	–	0.01%	38
2019 Q2	$30K	Hold	350	–	–	0.02%	38
2019 Q1	$31K	Hold	350	–	–	0.02%	37
2018 Q4	$30K	Hold	350	–	–	0.02%	36
2018 Q3	$34K	Buy	+350	New	+$34.9K	0.02%	37

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MayTech Global Investments's BMRN Position: Q1 2023 in Review

MayTech Global Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 350 shares — an estimated $36.2K sold.

MayTech Global Investments first reported a position in BMRN in Q3 2018 and held it in 17 quarters. The position peaked at $43K in Q2 2020. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

MayTech Global Investments reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
MayTech Global Investments sold 350 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $36.2K.
MayTech Global Investments first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 17 quarters.
MayTech Global Investments's BioMarin Pharmaceuticals position peaked at $43K in Q2 2020.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on MayTech Global Investments's 13F filing for Q1 2023, filed 11 May 2023.